Rigel Pharmaceuticals

Scholar thinks Glaxo made a wise move to back Merck

Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.

October 11, 2018

Hope on the horizon for rare kidney disease

Loosening of clinical requirements has encouraged more projects into the IgA nephropathy pipeline, with a steroid–based approach from Sweden’s Calliditas looking particularly promising.

September 21, 2018

Upcoming events – Phase II readouts loom for Concert and Reata

Concert hopes to give Pfizer a run for its money in alopecia, while Reata looks to continue its renaissance with more Phoenix data.

April 20, 2018

Snippet roundup: new CAR-Ts for old, and an unusual win for Alkermes

April 03, 2018

Rigel gets bad news ahead of its biggest date yet

August 31, 2016

Rigel gets another chance with fostamatinib

July 08, 2016

Upcoming events – Vesneo’s decision date and fostamatinib’s next try

September 18, 2015

Buying in growth beats innovation for pharma

May 19, 2015

Dry eye development reaches the Eleventh hour

April 16, 2015

Therapy focus – Beyond blood pressure control for IgA nephropathy

February 24, 2015

Flexus shows other immuno-oncology wannabes how it's done

Load More